The future for early-stage tuberculosis drug discovery

Future Microbiology

Volumn 10, Issue 2, 2015, Pages 217-229

  Zuniga, Edison S ^a   Early, Julie ^a   Parish, Tanya ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

drug target; essential genes; high throughput screening; Mycobacterium tuberculosis; tuberculosis drug discovery

Indexed keywords

TUBERCULOSTATIC AGENT;

CHEMICAL GENETICS; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; DRUG DESIGN; DRUG EFFECTS; GENETICS; MICROBIOLOGY; PRECLINICAL STUDY;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84923180646     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.125     Document Type: Review

References (100)

1. Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. Contribution of effux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 12(4), 695-700 (2012).
2. Calvori C, Frontali L, Leoni L, Tecce G. Effect of rifamycin on protein synthesis. Nature 207(995), 417-418 (1965).
3. Takayama K, Wang L, David HL. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2(1), 29-35 (1972).
4. Timmins GS, Master S, Rusnak F, Deretic V. Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48(8), 3006-3009 (2004).
5. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33(9), 1493-1499 (1989).
6. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537-544 (1998).
7. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J. Bacteriol. 184(19), 5479-5490 (2002).
8. Lew JM, Kapopoulou A, Jones LM, Cole ST. TubercuList-10 years after. Tuberculosis (Edinb.) 91(1), 1-7 (2011).
9. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6(1), 29-40 (2007).
10. Working Group on New TB Drugs. Discovery portfolio. www.newtbdrugs.org/pipeline-discovery.php
11. Galandrin S, Guillet V, Rane RS et al. Assay development for identifying inhibitors of the mycobacterial FadD32 activity. J. Biomol. Screen. 18(5), 576-587 (2013).
12. Kumar A, Casey A, Odingo J et al. A high-throughput screen against pantothenate synthetase (PanC) identifes 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis. PLoS ONE 8(11), e72786 (2013).
13. Lin Y, Zhu N, Han Y, Jiang J, Si S. Identifcation of anti-tuberculosis agents that target the cell-division protein FtsZ. J. Antibiot. (Tokyo) 67 (9), 671-676 (2014).
14. Wilsey C, Gurka J, Toth D, Franco J. A large scale virtual screen of DprE1. Commun. Integr. Biol. 47, 121-125 (2013).
15. Pauli I, Dos Santos RN, Rostirolla DC et al Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. J. Chem. Inf. Model. 53(9), 2390-2401 (2013).
16. Abrahams GL, Kumar A, Savvi S et al. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem. Biol. 19(7), 844-854 (2012).
17. Flipo M, Willand N, Lecat-Guillet N et al. Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. J. Med. Chem. 55(14), 6391-6402 (2012).
18. White EL, Southwork K, Ross L et al. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J. Biomol. Screen. 12(1), 100-105 (2007).
19. Radusky L, Defelipe LA, Lanzarotti E et al. TuberQ: a Mycobacterium tuberculosis protein druggability database. Database (Oxford) 2014, 1-10 (2014).
20. Pai R, Ioerger TR. Target explorer (prototype). http://saclab.tamu.edu/target-explorer.html
21. Camus JC, Pryor MJ, Médigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148(Pt 10), 2967-2973 (2002).
22. Lechartier B, Rybniker J, Zumla A, Cole ST. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol. Med. 6(2), 158-168 (2014).
23. Wei JR, Krishnamoorthy V, Murphy K et al. Depletion of antibiotic targets has widely varying effects on growth. Proc. Natl Acad. Sci. USA 108(10), 4176-4181 (2011).
24. Cheng N, Porter MA, Frick LW et al. Filtration improves the performance of a high-throughput screen for anti-mycobacterial compounds. PLoS ONE 9(5), e96348 (2014).
25. Franzblau SG, Degroote MA, Cho SH et al. Comprehensive ana-lysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 92(6), 453-458 (2012).
26. Stanley SA, Grant SS, Kawate T et al. Identifcation of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7(8), 1377-1384 (2012).
27. Pethe K, Sequeira PC, Agarwalla S et al. A chemical genetic screen in Mycobacterium tuberculosis identifes carbon-source-dependent growth inhibitors devoid of in vivo effcacy. Nat. Commun. 1, 57 (2010).
28. Altaf M, Miller CH, Bellows DS, O'toole R. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb.) 90(6), 333-337 (2010).
29. Wang F, Sambandan D, Halder R et al. Identifcation of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc. Natl Acad. Sci. USA 110(27), E2510-E2517 (2013).
30. Gold B, Pingle M, Brickner SJ et al. Nonsteroidal anti-infammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc. Natl Acad. Sci. USA 109(40), 16004-16011 (2012).
31. Christophe T, Jackson M, Jeon HK et al. High content screening identifes decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5(10), e1000645 (2009).
32. Ramón-García S, Ng C, Anderson H et al. Synergistic drug combinations for tuberculosis therapy identifed by a novel high-throughput screen. Antimicrob. Agents Chemother. 55(8), 3861-3869 (2011).
33. Stanley SA, Barczak AK, Silvis MR. Identifcation of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10(2), e1003946 (2014).
34. Sundaramurthy V, Barsacchi R, Samusik N et al. Integration of chemical and RNAi multiparametric profles identifes triggers of intracellular mycobacterial killing. Cell Host Microbe 13(2), 129-142 (2013).
35. Ananthan S, Faaleolea ER, Goldman RC et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb.) 89(5), 334-353 (2009).
36. Maddry JA, Ananthan S, Goldman RC et al. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb.) 89(5), 354-363 (2009).
37. Islam MS, Richards JP, Ojha AK. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial bioflms. Expert Rev. Anti. Infect. Ther. 10(9), 1055-1066 (2012).
38. Grant SS, Kawate T, Nag PP et al. Identifcation of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem. Biol. 8(10), 2224-2234 (2013).
39. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 5707 (2005).
40. Sacksteder KA, Protopopova M, Barry CE, Iii, Andries K, Nacy CA. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 7(7), 823-837 (2012).
41. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profling. Commun. Integr. Biol. 2(3), 215-218 (2009).
42. Makarov V, Manina G, Mikusova K et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928), 801-804 (2009).
43. Makarov V, Lechartier B, Zhang M et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 6(3), 372-383 (2014).
44. La Rosa V, Poce G, Canseco JO et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56(1), 324-331 (2012).
45. Grzegorzewicz AE, Pham H, Gundi VA et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8(4), 334-341 (2012).
46. Remuiñán MJ, Pérez-Herrán E, Rullás J et al. Tetrahydropyrazolo[1, 5-a]pyrimidine-3-carboxamide and N-benzyl-6', 7'-dihydrospiro[piperidine-4, 4'-thieno[3, 2-c] pyran] analogues with bactericidal effcacy against Mycobacterium tuberculosis targeting MmpL3. PLoS ONE 8(4), e60933 (2013).
47. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(4), 1797-1809 (2012).
48. Rao SP, Lakshminarayana SB, Kondreddi RR et al. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl. Med. 5(214), 214ra168 (2013).
49. Shirude PS, Shandil R, Sadler C et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are effcacious in vivo. J. Med. Chem. 56(23), 9701-9708 (2013).
50. Naik M, Humnabadkar V, Tantry SJ et al. 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity J. Med. Chem. 57(12), 5419-5434 (2014).
51. Panda M, Ramachandran S, Ramachandran V et al. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J. Med. Chem. 57(11), 4761-4771 (2014).
52. Tiwari R, Möllmann U, Cho S, Franzblau SG, Miller PA, Miller MJ. Design and syntheses of anti-tuberculosis agents inspired by BTZ043 using a scaffold simplifcation strategy. ACS Med. Chem. Lett. 5(5), 587-591 (2014).
53. Mak PA, Rao SP, Ping Tan M et al. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7 (7), 1190-1197 (2012).
54. Stanley SA, Kawate T, Iwase N et al. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc. Natl Acad. Sci. USA 110 (28), 11565-11570 (2013).
55. Ishizaki Y, Hayashi C, Inoue K et al. Inhibition of the frst step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J. Biol. Chem. 288(42), 30309-30319 (2013).
56. Goldman RC. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb.) 93(6), 569-588 (2013).
57. Kraus CN. Low hanging fruit in infectious disease drug development. Curr. Opin. Microbiol. 11(5), 434-438 (2008).
58. Merle C, Fielding K, Lapujade O et al. A randomised controlled trial of a 4-month gatifoxacin-containing regimen vs. standard 6-month regimen for treating drug-susceptible pulmonary tuberculosis: main effcacy and safety results of the OFLOTUB trial. Presented at: 44th Union World Conference on Lung Health. Paris, France, 30 October-3 November 2013.
59. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann. NY Acad. Sci. 1241, 48-70 (2011).
60. Alffenaar JW, Van Der Laan T, Simons S et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob. Agents Chemother. 55 (3), 1287-1289 (2011).
61. Balasubramanian V, Solapure S, Iyer H et al. Bactericidal activity and mechanism of action of AZD5847: a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother. 58(1), 495-502 (2014).
62. Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367(17), 1508-1518 (2012).
63. Sotgiu G, Centis R, D'ambrosio L, Spanevello A, Migliori GB; International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are confrmed by experimental evidence. Eur. Respir. J. 42(1), 288-290 (2013).
64. Zhang D, Lu Y, Liu K et al. Identifcation of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J. Med. Chem. 55(19), 8409-8417 (2012).
65. Rosenthal IM, Zhang M, Williams KN et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4(12), e344 (2007).
66. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40(11), 2655-2657 (1996).
67. Yang B, Koga H, Ohno H et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 42(5), 621-628 (1998).
68. Dietze R, Teixeira L, Rocha LM et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 45 (7), 1972-1976 (2001).
69. Gill SK, Xu H, Kirchhoff PD et al. Structure-based design of novel benzoxazinorifamycins with potent binding affnity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases. J. Med. Chem. 55(8), 3814-3826 (2012).
70. Zhang L, Pornpattananangkul D, Hu C-MJ, Huang C-M. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 17(6), 585-594 (2010).
71. Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: facts, faws, and future. Nanomedicine 7(3), 259-272 (2011).
72. Hauck TS, Giri S, Gao Y, Chan WC. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv. Drug Deliv. Rev. 62(4-5), 438-448 (2010).
73. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb.) 83(6), 373-378 (2003).
74. Pandey R, Khuller GK. Solid lipid particle based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb.) 85(4), 227-234 (2005).
75. Altin T, Ozcan O, Turhan S et al. Torsade de pointes associated with moxifoxacin: a rare but potentially fatal adverse event. Can. J. Cardiol. 23(11), 907-908 (2007).
76. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifoxacin and torsade de pointes. Ann. Pharmacother. 41(2), 336-340 (2007).
77. Koide T, Shiba M, Tanaka K et al. Severe QT interval prolongation associated with moxifoxacin: a case report. Cases J. 409, 1 (2008).
78. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fuoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol. 59(1), 122-126 (2001).
79. + channel blockade by the fuoroquinolone antibiotic moxifoxacin. Br. J. Pharmacol. 147(8), 905-916 (2006).
80. Ryu S, Imai YN, Oiki S. The synergic modeling for the binding of fuoroquinolone antibiotics to the hERG potassium channel. Bioorg. Med. Chem. Lett. 23(13), 3848-3851 (2013).
81. Kerns EH, Di L. Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization (1st Edition). Academic Press, MA, USA (2008).
82. + channel blockade: exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. J. Med. Chem. 56(7), 2828-2840 (2013).
83. Reck F, Alm R, Brassil P et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J. Med. Chem. 54(22), 7834-7847 (2011).
84. Reck F, Alm RA, Brassil P et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profle. J. Med. Chem. 55 (15), 6916-6933 (2012).
85. Hameed PS, Patil V, Solapure S et al. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo effcacy against Mycobacterium tuberculosis. J. Med. Chem. 57(11), 4889-4905 (2014).
86. Ioerger TR, O'malley T, Liao R et al. Identifcation of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONEe 8(9), e75245 (2013).
87. Gavrish E, Sit CS, Cao S et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem. Biol. 21(4), 509-528 (2014).
88. Butcher RA, Schreiber SL. Using genome-wide transcriptional profling to elucidate small-molecule mechanism. Curr. Opin. Chem. Biol. 9(1), 25-30 (2005).
89. Boshoff HI, Myers TG, Copp BR, Mcneil MR, Wilson MA, Barry CE 3rd. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279, 40174-40184 (2004).
90. Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 6, 263-269 (2012).
91. Prosser GA, De Varvalho LP. Metabolomics deveal D-Alanine:D-Alanine ligase as the target of D-cycloserine in Mycobacterium tuberculosis. ACS Med. Chem. Lett. 4, 1233-1237 (2013).
92. Lomenick B, Hao R, Jonai N et al. Ta rg e t identifcation using drug affnity responsive target stability (DARTS). Proc. Natl Acad. Sci. USA 106(51), 21984-21989 (2009).
93. Martínez-Jiménez F, Papadatos G, Yang L et al. Target prediction for an open access set of compounds active against Mycobacterium tuberculosis. PLoS Comput. Biol. 9 (10), e1003253 (2013).
94. Prathipati P, Ma NL, Manjunatha UH, Bender A. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. J. Proteome Res. 8(6), 2788-2798 (2009).
95. Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications PLoS Comput. Biol. 6 (11), e1000976 (2010).
96. Seven pharmaceutical companies join academic researchers to speed TB drug discovery. www.idri.org/press-6-25-12.php
97. The Lilly TB drug discovery initiative. www.tbdrugdiscovery.org
98. MM4TB more medicines for tuberculosis. www.mm4tb.org
99. We bT B. www.webtb.org
100. Tuberculosis trials consortium (TBTC). www.cdc.gov